Kidney disease treatment is undergoing a transformation, driven by exciting new research that reveals the protective power of semaglutide in patients with type 2 diabetes. Semaglutide, a medication ...

In the phase 2 MIRO-CKD trial, 12 weeks of balcinrenone combined with dapagliflozin reduced albuminuria compared with dapagliflozin alone added to standard of care in patients with stage 3-4 CKD.

New CKD biomarkers reveal tubular injury and repair pathways, enhancing personalised treatment strategies. Learn more about ...

Jennifer Green, MD, provides considerations for the use of SGLT2 inhibitors in treatment of CKD. Ryan Haumschild, PharmD, MS, MBA: As we talk about SGLT2s [sodium-glucose cotransporter-2 inhibitors] ...

Dapagliflozin reduced left ventricular mass index early into treatment in patients with nondialysis-dependent CKD, regardless of disease etiology and cardiovascular history. Dapagliflozin reduces left ...

Chronic kidney disease (CKD) happens when your kidneys gradually lose their ability to filter waste products and excess fluid from your blood. At first, it typically causes no symptoms, but as your ...

The European Renal Association (ERA) kicks off its 61st ERA Congress in Stockholm, Sweden, with a theme of "Rethinking kidney health, transforming kidney care," and a program full of sessions delving ...

Kidney disease is a serious yet often overlooked condition that affects millions worldwide. Despite its impact, it is frequently underestimated compared to illnesses like cancer and heart disease. The ...

Kidney disease is the third-fastest-growing cause of death globally. Here's why doctors are sounding the alarm. Kidney disease is a serious yet often overlooked condition that affects millions ...